Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: Compugen is a biotechnology discovery company focused on therapeutic and diagnostic product candidates. The company utilizes proprietary computational platforms ("discovery engines") to identify novel proteins and biomarkers. In December 2005, the company underwent a reorganization to focus resources on research and development, resulting in a 25% reduction in its workforce. The company has shifted its strategy from selling software products to out-licensing discovered product candidates to pharmaceutical and diagnostic partners.
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 (in thousands) | 2004 (in thousands) |
|---|---|---|
| Revenues | $646 | $2,630 |
| Total Operating Expenses | $15,524 | $18,207 |
| Operating Loss | $(14,878) | $(15,577) |
| Net Loss | $(13,978) | $(13,722) |
| Net Loss Per Share (Basic & Diluted) | $(0.50) | $(0.50) |
| Cash and Cash Equivalents | $8,492 | $4,366 |
| Total Liquid Assets (Cash + Short/Long-term Securities) | $36,804 | $48,402 |
| Total Assets | $42,106 | $55,353 |
| Accumulated Deficit | $(119,734) | $(105,756) |
| Shareholders' Equity | $36,248 | $49,566 |
Note: Governmental and other grants totaling $2.254 million in 2005 were reclassified from revenue to a deduction from research and development expenses.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by approximately 75% to $646,000 in 2005 from $2.63 million in 2004. This decline is primarily due to the cessation of sales for legacy software products (LEADS, OligoLibraries) as the company pivoted to a discovery and licensing model.
- Expense Reduction: Total operating expenses decreased by 15% to $15.5 million, driven by a 28% reduction in selling and marketing expenses and a 16% reduction in general and administrative expenses following the December 2005 reorganization.
- Liquidity Position: While cash and cash equivalents increased to $8.5 million, total liquid assets (including marketable securities) decreased from $48.4 million in 2004 to $36.8 million in 2005 due to the redemption of long-term securities.
- Financial Income: Net financial income decreased by 52% to $682,000, attributed to lower interest rates on structured notes and reduced cash balances.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance
- Profitability: Management expects to continue incurring net losses in the near future. The company does not anticipate achieving profitability in the near term.
- Cash Runway: As of December 31, 2005, management believes existing cash and marketable securities are sufficient to fund operations for at least the next two years. However, additional financing will be required within that timeframe.
- Strategic Focus: The company intends to generate revenue through milestone payments and royalties from collaborators (e.g., Ortho-Clinical Diagnostics, Biosite, Diagnostic Product Corporation) rather than direct product sales.
Material Risks and Contingencies
- Subsidiary Going Concern: The wholly-owned subsidiary, Keddem Bioscience Ltd., faces substantial doubt regarding its ability to continue as a going concern. Its external auditors have raised this issue, and its operations depend on raising additional capital within the next few months. Failure to do so could result in the loss of all investments made in Keddem.
- Capital Requirements: The company may need to raise additional capital. If raised through equity issuance, existing shareholders will experience dilution. Failure to secure funding could force the curtailment of discovery activities.
- Accounting Changes: The adoption of SFAS No. 123(R) effective January 1, 2006, will require the company to record stock-based compensation expense, which may significantly increase reported financial losses.
- Grant Dependency: The company relies on research grants from the Israeli government and other bodies. Failure to comply with grant terms or secure future grants could materially harm financial results.
- Intellectual Property: Success depends on obtaining and maintaining patent protection for gene-based products, which involves complex legal uncertainties and competition from third-party IP rights.
Investor Verification Checklist
- Keddem Bioscience Funding: Verify whether Keddem Bioscience has successfully secured the necessary capital to continue operations, as its failure would result in a total loss of the parent company's investment in that subsidiary.
- Collaboration Milestones: Monitor the progress of collaborations with Ortho-Clinical Diagnostics, Biosite, and Diagnostic Product Corporation to determine if they will generate the anticipated milestone payments and royalties.
- Capital Raising Plans: Assess the company's ability to raise additional financing within the projected two-year runway without excessive dilution.
- Impact of SFAS 123(R): Review future financial statements to quantify the impact of the new stock-based compensation accounting standard on reported net losses.
- Grant Compliance: Confirm continued eligibility for Israeli government research and development grants, which offset a significant portion of R&D expenses.